What question did this study set out to answer?

To evaluate the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on major adverse cardiovascular events, cause-specific outcomes, and all-cause mortality across randomized clinical trials.

August 23, 2012Diabetes Obesity and MetabolismOpen Access

Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

View Full Paper

Ask AI

Bookmark

Why the study?

Do dipeptidyl peptidase-4 inhibitors reduce major cardiovascular events in patients with type 2 diabetes?

Population

70 randomized trials pooling 41,959 patients with type 2 diabetes

Comparison

Dipeptidyl peptidase-4 inhibitors for ≥24 weeks vs Placebo or other drugs

Design

Meta-analysis

Follow-up

mean 44.1 weeks

Authors

MMMatteo MonamiUniversity of Florence BÅBo ÅhrénLinköping University IDIlaria DicembriniEnvironment Agency

Discussion

Member takes

Implication

Supports DPP-4 inhibitor use for CV risk reduction in type 2 diabetes; reinforces randomized evidence across 70 trials.

Key Points

To evaluate the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on major adverse cardiovascular events, cause-specific outcomes, and all-cause mortality across randomized clinical trials.
Searched published and unpublished randomized trials (duration ≥24 weeks) comparing DPP-4 inhibitors with placebo or active comparators.
Analyzed data from 70 trials enrolling N=41,959 patients with a mean follow-up of 44.1 weeks using random-effects Mantel-Haenszel odds ratios (MH-OR).
Assessed changes in glycated hemoglobin, lipid profiles, and blood pressure to estimate expected myocardial infarction risk using the UKPDS risk engine.
Treatment with DPP-4 inhibitors significantly reduced MACE (MH-OR 0.71, 95% CI [0.59, 0.86]) and all-cause mortality (MH-OR 0.60, 95% CI [0.41, 0.88]).
DPP-4 inhibitors significantly lowered the risk of myocardial infarction (MH-OR 0.64, 95% CI [0.44, 0.94]), while the effect on stroke did not reach statistical significance (MH-OR 0.77, 95% CI [0.48, 1.24]).

Structured PICO

Do dipeptidyl peptidase-4 inhibitors reduce major cardiovascular events in patients with type 2 diabetes?

Population

70 randomized trials pooling 41,959 patients with type 2 diabetes

Intervention

Dipeptidyl peptidase-4 inhibitors (DPP4i) for ≥24 weeks

Comparator

Placebo or other drugs

Outcome

Major cardiovascular events (MACE) reported as serious adverse eventscomposite

Dipeptidyl peptidase-4 inhibitors appear to reduce the risk of major cardiovascular events, particularly myocardial infarction, and all-cause mortality in patients with type 2 diabetes.

Cite This Study

Monami et al. (2012) studied this question.

synapsesocial.com/papers/6a73eac1c973d0bd5a69fa32 https://doi.org/10.1111/dom.12000

View Full Paper

Ask AI

Bookmark

Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider